The Molecular Recognition Shared Resource (MRSR) is a newly established core facility. The goal of the MRSR is to provide investigators with reagents, equipment, and expertise for the production, detection and characterization of biomolecules. The MRSR is composed of three individual Resources , the Antibody Resource, the Protein Expression Resource and the BIAcore Resource. Each of these resources provides unique, cost- effective services and expertise for Vanderbilt Cancer Center (VCC) and University Investigators. The goals and the objectives of three resources are described below. The goal of the Antibody Resource is to provide the expertise, reagents and equipment for the production, detection, characterization, purification and labeling of traditional polyclonal, monoclonal and phage-displayed or soluble ScFv recombinant antibodies. Assays incorporating antibodies can also be developed to detect and/or quantitate proteins, carbohydrates or nucleic acids which occur individually or as components of a biological milieu. The objective of the Antibody Resource is to provide antibodies and antibody-based assays to VCC and University Investigators on a timely and cost-effective basis. The goal of the Protein Expression Resource is to provide VCC and University Investigators with reagents and equipment for large scale protein expression using the baculovirus expression system. Additionally, Investigators are provided with equipment necessary to harvest large amounts of cellular material. The goal and objective of the BIAcore Resource is to provide VCC and University Investigators with access to the BIAcore 2000, an instrument from BIAcore, AB., that performs real-time biomolecular interaction analysis using surface plasmon resonance technology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA068485-05S2
Application #
6398978
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
Budget End
Support Year
5
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Paul, Pritha; Rellinger, Eric J; Qiao, Jingbo et al. (2017) Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma. Oncotarget 8:82609-82620
Stephenson, Jason R; Wang, Xiaohan; Perfitt, Tyler L et al. (2017) A Novel Human CAMK2A Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and Causes ASD-Related Behaviors. J Neurosci 37:2216-2233
Bouziat, Romain; Hinterleitner, Reinhard; Brown, Judy J et al. (2017) Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356:44-50
Moyo, T K; Wilson, C S; Moore, D J et al. (2017) Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 36:4653-4661
Vilgelm, Anna E; Cobb, Priscilla; Malikayil, Kiran et al. (2017) MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine 24:43-55
LePage, Daniel P; Metcalf, Jason A; Bordenstein, Sarah R et al. (2017) Prophage WO genes recapitulate and enhance Wolbachia-induced cytoplasmic incompatibility. Nature 543:243-247
Li, Jun; Smith, Jarrod A; Dawson, Eric S et al. (2017) Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 28:1016-1023
Zhang, Juliet; Weinrich, Jarret A P; Russ, Jeffrey B et al. (2017) A Role for Dystonia-Associated Genes in Spinal GABAergic Interneuron Circuitry. Cell Rep 21:666-678
Aune, T M; Crooke 3rd, P S; Patrick, A E et al. (2017) Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. J Autoimmun 81:99-109
Esbenshade, Adam J; Zhao, Zhiguo; Aftandilian, Catherine et al. (2017) Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer 123:3781-3790

Showing the most recent 10 out of 2332 publications